Veloxis doses first patient in Phase 2 trial of transplant drug pegrizeprument
Veloxis Pharmaceuticals, a specialty transplant-medicine company owned by Japan's Asahi Kasei, said on 31 August 2026 that it has dosed the first patient in RENGEVITY-201, a Phase 2 trial of pegrizeprument in people who have received a kidney transplant.
The problem the drug targets is organ rejection: after a transplant, the immune system attacks the new organ, so patients must take anti-rejection medicines for life. The current mainstays (calcineurin inhibitors) work but can gradually damage the very kidney they are meant to protect. Pegrizeprument (also known as VEL-101 or FR104) is an antibody-based drug designed to calm the immune attack through a different route — blocking a T-cell signal called CD28 — in the hope of preventing rejection with less long-term harm.
RENGEVITY-201 is a randomised, multicentre trial testing the drug's safety and effectiveness against standard care. Pegrizeprument already holds US orphan drug status for preventing rejection in liver transplant recipients, granted in January 2026.